Orphan Designation Requests To Get Slower US FDA Reviews
This article was originally published in SRA
The US Food and Drug Administration has extended its deadline for delivering an orphan drug designation decision, placing more pressure on sponsors to ensure requests contain no problems from the start.
You may also be interested in...
Stakeholders wonder about impact of placing orphan drug program staff "into review teams" as part of next iteration of user fee program.
Delaware district judge rules against AstraZeneca’s claim the IRA violates its due process rights, echoing findings made by Ohio district judge in Chamber of Commerce’s suit. Only other IRA ruling to date dismissed PhRMA’s complaint on procedural grounds without addressing the merits.
Lumicell’s Cancer Imaging Drug Faces Clinical Meaningfulness, Anaphylaxis Risk Questions At FDA Panel
US FDA advisory committee briefing documents say drug-device combo Lumisight (pegulicianine) is effective at picking up cancer but it is not clear whether that translates to patient benefit.